Immune thrombocytopenia (<scp>ITP</scp>) <scp>World Impact Survey</scp> (<scp>I‐WISh</scp>): Impact of <scp>ITP</scp> on health‐related quality of life

Cooper, Nichola; Kruse, A; Kruse, Caroline; Watson, Shirley; Morgan, Mervyn; Arnold, Donald M.; Tomiyama, Yoshiaki; Santoro, Cristina; Michel, Marc; Laborde, Serge; Lovrenčič, Barbara; Hou, Ming; Bailey, Tom; Taylor‐Stokes, Gavin; Haenig, Jens; Bussel, James B.

doi:10.1002/ajh.26036

Cited by 74 publications

(62 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among patients who responded, fatigue was cited as the most frequent symptom 2 . Reductions in energy level, capacity to exercise, and ability to perform daily tasks were common 1 . The patient and physician reports of symptom burden were similar, although patients more often cited fatigue than did physicians 2 .…”

mentioning

confidence: 99%

“…In this issue of the American Journal of Hematology , two articles by Nichola Cooper and colleagues describe results from the immune thrombocytopenia (ITP) World Impact Survey (I‐WISh) and the ITP Life Quality Index (ILQI) among 1507 adults (age ≥ 18) with ITP and 313 hematologists and 159 hemato‐oncologists treating ITP patients across 13 countries 1,2 . There are two versions of the I‐WISh: the first is for patients with ITP, and the second is for hematologists or hemato‐oncologists that treat patients with ITP.…”

mentioning

confidence: 99%

“…Physicians agreed about the impact of ITP: 69% believed that patients' anxiety about platelet levels had a negative impact on their emotional well‐being. Almost half (49%) of patients reduced or seriously considered reducing their working hours (including 29% who had considered terminating employment), and over one‐third (36%) of those employed reported that ITP decreased their productivity at work 1 . The percentage reporting negative impacts to work productivity were higher among those aged 18‐49 years (40%) than among those aged 50 and older (27%).…”

mentioning

confidence: 99%

“…Many patients experienced delays in diagnosis for a variety of reasons (including waiting to see a specialist, or misdiagnoses), and 63% wished they had received more support at the time of their diagnosis, particularly from their physician 2 . However, 77% felt their physician considered their needs when planning their treatment goals, which was similar across age and gender 1 . Satisfaction with ITP treatment varied by the type of treatment received: 79% of those receiving anti‐CD20 agents reported satisfaction regarding control of their ITP.…”

mentioning

confidence: 99%

“…2 However, 77% felt their physician considered their needs when planning their treatment goals, which was similar across age and gender. 1 Satisfaction with ITP treatment varied by the type of treatment received: 79% of those receiving anti-CD20 agents reported satisfaction regarding control of their ITP.…”

mentioning

confidence: 99%

See 4 more Smart Citations

I‐WISh: A wish list for immune thrombocytopenia quality of life indicators becomes reality

Mathias

2020

American J Hematol

View full text Add to dashboard Cite

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

I‐WISh: A wish list for immune thrombocytopenia quality of life indicators becomes reality

Mathias

2020

American J Hematol

View full text Add to dashboard Cite

Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment

Cooper

Kruse²,

Kruse³

et al. 2020

American J Hematol

Self Cite

View full text Add to dashboard Cite

Immune thrombocytopenia (ITP) is now well-known to reduce patients' health-related quality of life. However, data describing which signs and symptoms patients and physicians perceive as having the greatest impact are limited, as is understanding the full effects of ITP treatments. I-WISh (ITP World Impact Survey) was an exploratory, cross-sectional survey designed to establish the multifaceted impact of ITP, and its treatments, on patients' lives. It focused on perceptions of 1507 patients and 472 physicians from 13 countries regarding diagnostic pathway, frequency and

show abstract

Single‐dose versus low‐dose rituximab in corticosteroid‐resistant or relapsed ITP: A multicenter, randomized, controlled study

Yuan

et al. 2022

American J Hematol

Self Cite

View full text Add to dashboard Cite

Primary immune thrombocytopenia (ITP) is an autoimmune bleeding disorder, in which rituximab (RTX) induces the best long-term effect among recommended second-line treatments. Nevertheless, the optimal regimen of RTX remains unclear. We herein conducted a prospective, multicenter, open-label, randomized controlled trial to compare the efficacy and safety of RTX at two different dosage regimens in patients with corticosteroid-resistant or relapsed ITP. Recruited patients were randomly assigned (1:1) to receive either RTX at a repeated low dose (100 mg weekly for 4 weeks, LD-RTX) or at a single dose (375 mg/m 2 , S-RTX). Overall response was achieved in 64.3% of patients who received LD-RTX versus 67.4% of those receiving S-RTX (p = .759). The complete response (CR) rate was 23.8% after LD-RTX and 28.3% after S-RTX (p = .635). In health-related quality of life, S-RTX improved patients' psychological status, quality of life, social activities, and work compared with LD-RTX. Furthermore, S-RTX significantly reduced physician visits without compromising efficacy. Our findings demonstrate that a S-RTX is comparable to LD-RTX in effectiveness and safety for treatment of corticosteroid-resistant or relapsed ITP. The single-dosage regimen optimizes the use of medical resources, improves the cost-effectiveness of RTX, and represents a promising and more convenient replacement for LD-RTX in ITP. This study has been completed and is registered with ClinicalTrials.gov, number NCT03258866. | INTRODUCTIONPrimary immune thrombocytopenia (ITP) is an acquired immune-mediated disorder in which both increased platelet destruction and impaired platelet production result in low platelet counts, an increased risk of bleeding, and a diminished health-related quality of life (HRQoL). [1][2][3][4][5] It is mainly caused by pathological antiplatelet autoantibodies, T-cell abnormality, and impaired megakaryocyte generation. The standard initial treatments include corticosteroids and intravenous immunoglobulin 6-8 ; however, unfortunately, only 20%-30% of patients achieve a durable response, while the majority require further therapy. 9,10 Rituximab (RTX) is an anti-CD20 chimeric monoclonal antibody 11 that targets B cells and induces reversible B-cell depletion. RTX is effective in the treatment of ITP and recommended as a second-line treatment

show abstract

Immune thrombocytopenia (ITP) World Impact Survey (I‐WISh): Impact of ITP on health‐related quality of life

Cited by 74 publications

References 14 publications

I‐WISh: A wish list for immune thrombocytopenia quality of life indicators becomes reality

I‐WISh: A wish list for immune thrombocytopenia quality of life indicators becomes reality

Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment

Single‐dose versus low‐dose rituximab in corticosteroid‐resistant or relapsed ITP: A multicenter, randomized, controlled study

Contact Info

Product

Resources

About